Comparative Benefits of Statins in Coronary Heart Disease

Abstract

Hyperlipidemia is one of the main risk factors for coronary heart disease (CHD), thus the treatment of the lipid metabolism disorders is the main measure to prevent the development and progression of this disease. The purpose of the research is a comparative study of atorvastatin, rosuvastatin, and simvastatin's hypolipidemic effect by determining the content of a lipoprotein fraction in the dynamics of statin therapy, as well as to study their negative effect on glucose metabolism. For the study, 150 people aged (57.86 ± 4.59) years were examined for CHD (stable angina pectoris II functional class). All patients received basic CHD therapy: one 5-mg tablet of bisoprolol a day, one 75-mg tablet of aspirin a day, and short-acting nitrates for angina attacks. The patients had also been receiving statin therapy, depending on which the patients were divided into three groups (in each of 50 people): group 1 -one 20-mg tablet of simvastatin a day; group 2 -one 20-mg tablet of atorvastatin a day; group 3 -one 10-mg tablet of rosuvastatin a day. The patients taking simvastatin were observed with a significant decrease of cholesterol at the end of the 12-week treatment, by 24.7% (p < 0.05) compering to the atorvastatin group by 34.75% (p < 0.05) and rosuvastatin -by 36.96% (p < 0.05); triglycerides -by 16.2% (p < 0.05), 20.1% (p < 0.05), and 22.7% (p < 0.05), respectively; low density lipoproteins -by 24.5% (p < 0.05), 35% (p < 0.05), and 38.7% (p < 0.05) while the increase of high density lipoproteins was noted -by 20.4% (p < 0.05), 28.2% (p < 0.05), and 39.5% (p < 0.05), respectively, and AIP significantly decreased by 34% (p < 0.05), 41.8% (p < 0.05), and 64.1% (p < 0.05). Statin therapy with atorvastatin and rosuvastatin is more effective compared with simvastatin according to lipid profile, and rosuvastatin is more effective than atorvastatin based on the increase of high-density lipoproteins.